Byondis
Eric van Hooren is a seasoned professional in clinical development with extensive experience spanning over three decades. Currently serving as the Senior Director of Clinical Development at Byondis since May 2023, Eric plays a key role in defining and coordinating clinical strategies for R&D projects. Prior to this, Eric held the position of Chief Development Officer at Xenikos B.V., where responsibilities included overseeing the global clinical development of T-Guard for acute graft-versus-host disease. Eric's career also includes significant roles at Acerta Pharma, Merck, NV Organon, and AstraZeneca, contributing to the execution and management of various clinical trial programs. Eric holds a Drs degree in Biology from Radboud University and has a solid educational foundation from Gymnasium Bernrode in the Netherlands.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.